NCT00208234View on ClinicalTrials.gov

Effect of Xolair on Airway Hyperresponsiveness

PHASE4UnknownINTERVENTIONAL

Enrollment

22

Participants

Timeline

Start Date

January 31, 2004

Primary Completion Date

September 30, 2011

Study Completion Date

September 30, 2011

Conditions

Allergic Asthma

Interventions

DRUG

Omalizumab

0.016 mg/kg IgE

DRUG

Placebo for Omalizumab

Placebo

DRUG

omalizumab

Monoclonal antibody against IgE. 0.016 mg/kg IgE

Trial Locations (1)

68131

Creighton University Division of Allergy & Immunology, Omaha

Sponsors

Collaborators (1)

Genentech, Inc.

All Listed Sponsors

collaborator

Genentech, Inc.

INDUSTRY

lead

Creighton University

OTHER